Leerink Partners Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $35
Maintained Buy Rating on Myriad Genetics Amid GeneSight Study Discontinuation
Jefferies Upgrades Myriad Genetics(MYGN.US) to Buy Rating, Raises Target Price to $35
Myriad Genetics Price Target Raised to $34.00/Share From $29.00 by Scotiabank
Piper Sandler Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Raises Target Price to $34
Scotiabank Remains a Buy on Myriad Genetics (MYGN)
Myriad Genetics Analyst Ratings
Piper Sandler Maintains Neutral on Myriad Genetics, Raises Price Target to $30
Myriad Genetics Price Target Raised to $30.00/Share From $28.00 by TD Cowen
Myriad Genetics Analyst Ratings
JP Morgan Maintains Underweight on Myriad Genetics, Raises Price Target to $20
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
TD Cowen Keeps Their Hold Rating on Myriad Genetics (MYGN)
Myriad Genetics Analyst Ratings
Myriad Genetics Analyst Ratings
Myriad Genetics Inc.: Jefferies assumes an underwriting rating of underperformance; targets $20 to $25
Myriad Genetics Analyst Ratings
Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)
Myriad Genetics Analyst Ratings